Six-year follow up of imatinib therapy for newly diagnosed chronic myeloid leukemia in Iranian patients.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sepanlou Sadaf G, Parsaeian Mahboubeh, Krohn Kristopher J, Afshin Ashkan, Farzadfar Farshad, Roshandel Gholamreza, Karimkhani Chante, Bazargan-Hejazi Sharzad, Kiadaliri Aliasghar Ahmad, Ahmadieh Hamid, Djalalinia Shirin, Ebrahimi Hedyeh, Eshrati Babak, Esteghamati Ali Reza, Farvid Maryam S, Fereshtehnejad Seyed-Mohammad, Hafezi-Nejad Nima, Hassanvand Mohammad Sadegh, Heydarpour Pouria, Islami Farhad, Karimi Seyed M, Katibeh Marzieh, Khosravi Ardeshir, Khubchandani Jagdish, Mahdavi Mahdi, Pishgar Farhad, Qorbani Mostafa, Rahimi-Movaghar Vafa, Safi Sare, Sahraian Mohammad Ali, Shahraz Saeid, Sheikhbahaei Sara, Mohammadi Alireza, Mokdad Ali H, Vos Theo, Murray Christopher J L, Moradi-Lakeh Maziar, Naghavi Mohsen, Malekzadeh Reza
Аннотация
METHODS: We used the results of GBD 2015 to present the levels and trends of DALYs, life expectancy (LE), and HALE in Iran and its 15 neighboring countries from 1990 to 2015. For each country, we assessed the ratio of observed levels of DALYs and HALE to those expected based on socio-demographic index (SDI), an indicator composed of measures of total fertility rate, income per capita, and average years of schooling.
RESULTS: All-age numbers of DALYs reached over 19 million years in Iran in 2015. The all-age number of DALYs has remained stable during the past two decades in Iran, despite the decreasing trends in all-age and age-standardized rates. The all-cause DALY rates decreased from 47,200 in 1990 to 28,400 per 100,000 in 2015. The share of non-communicable diseases in DALYs increased in Iran (from 42% to 74%) and all of its neighbors between 1990 and 2015; the pattern of change is similar in almost all 16 countries. The DALY rates for NCDs and injuries in Iran were higher than global rates and the average rate in High Middle SDI countries, while those for communicable, maternal, neonatal, and nutritional disorders were much lower in Iran. Among men, cardiovascular diseases ranked first in all countries of the region except for Bahrain. Among women, they ranked first in 13 countries. Life expectancy and HALE show a consistent increase in all countries. Still, there are dissimilarities indicating a generally low LE and HALE in Afghanistan and Pakistan and high expectancy in Qatar, Kuwait, and Saudi Arabia. Iran ranked 11th in terms of LE at birth and 12th in terms of HALE at birth in 1990 which improved to 9th for both metrics in 2015. Turkey and Iran had the highest increase in LE and HALE from 1990 to 2015 while the lowest increase was observed in Armenia, Pakistan, Kuwait, Kazakhstan, Russia, and Iraq.
CONCLUSIONS: The levels and trends in causes of DALYs, life expectancy, and HALE generally show similarities between the 16 countries, although differences exist. The differences observed between countries can be attributed to a myriad of determinants, including social, cultural, ethnic, religious, political, economic, and environmental factors as well as the performance of the health system. Investigating the differences between countries can inform more effective health policy and resource allocation. Concerted efforts at national and regional levels are required to tackle the emerging burden of non-communicable diseases and injuries in Iran and its neighbors.